The risperidone outcomes study of effectiveness (ROSE) : A model for evaluating treatment strategies in typical psychiatric practice. Discussion.
Symposium "Pharmacoeconomic Factors Related to the Treatment of Schizophrenia". Chicago, IL, USA, 1998/04/08.
We describe the design of a multicenter, randomized clinical trial to compare clinical, quality-of-life, and economic outcomes in patients with schizophrenia or schizoaffective disorder who were treated with risperidone or any of 13 conventional antipsychotic drugs approved for use in the United States.
This I-year trial was designed to approximate conditions of typical clinical practice : protocolmandated care was minimized, and all health services (including medication) were provided according to usual community practices.
Measures of interest included changes in psychiatric symptoms, medication side effects, health-related quality of life, satisfaction with drug therapy, therapy switching, rehospitalization for the management of relapse, the use of psychiatric services of all types, and the cost of psychiatric care.
We review the rationale for this type of trial and discuss the potential value of such trials in setting policy and in clinical practice.
Mots-clés Pascal : Schizophrénie, Chimiothérapie, Traitement, Rispéridone, Neuroleptique, Atypique, Psychotrope, Efficacité traitement, Mesure, Etude longitudinale, Symptomatologie, Toxicité, Qualité vie, Satisfaction, Récidive, Analyse coût, Homme, Psychose, Changement médicament
Mots-clés Pascal anglais : Schizophrenia, Chemotherapy, Treatment, Risperidone, Neuroleptic, Atypical, Psychotropic, Treatment efficiency, Measurement, Follow up study, Symptomatology, Toxicity, Quality of life, Satisfaction, Relapse, Cost analysis, Human, Psychosis, Drug switching
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0190471
Code Inist : 002B02B03. Création : 16/11/1999.